139298-40-1
基本信息
(BASE),KN-93游離態(tài),鹽酸鹽,磷酸鹽各形式均有
CA2+/鈣調(diào)蛋白依賴性激酶Ⅱ(CA2+/CAM PKⅡ)競爭性抑制劑KN-3
N-[2-[N-(4-氯肉桂)-N-甲基氨基]苯基]-N-(2-羥乙基)-4-甲氧苯磺酰胺磷酸酯鹽
N-[2-[[[3-(4-氯苯基)烯丙基](甲基)氨基]甲基]苯基]-N-(2-羥乙基)-4-甲氧基苯磺酰胺
N-[2-[N-(4-氯肉桂)-N-甲基氨基]苯基]-N-(2-羥乙基)-4-甲氧苯磺酰胺磷酸酯鹽 100MG
(E)-N-(2-(((3-(4-氯苯基)烯丙基)(甲基)氨基)甲基)苯基)-N-(2-羥乙基)-4-甲氧基苯磺酰胺
N-[2-[[[3-(4-氯苯基)-2-丙烯-1-基]甲基氨基]甲基]苯基]-N-(2-羥基乙基)-4-甲氧基苯磺酰胺
物理化學性質(zhì)
安全數(shù)據(jù)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/08/19 | S6787 | N-[2-[N-(4-氯肉桂)-N-甲基氨基]苯基]-N-(2-羥乙基)-4-甲氧苯磺酰胺磷酸酯鹽 KN-93 | 139298-40-1 | 5mg | 1176.13元 |
2024/08/19 | S6787 | KN-93 | 139298-40-1 | 10mM (1mL in DMSO) | 1531.53元 |
2024/08/19 | K0055 | KN-93 KN-93 | 139298-40-1 | 5mg | 415元 |
常見問題列表
Target | Value |
CaMKII
(Cell-free assay) | 2.58 μM(Ki) |
After 2 days of KN-93 treatment, 95% of cells are arrested in G1. G1 arrest is reversible; 1 day after KN-93 release, a peak of cells had progressed into S and G2-M. KN-93 also blocks cell growth stimulated by basic fibroblast growth factor, platelet-derived growth factor-BB, and epidermal growth factor in NIH 3T3 fibroblasts. KN-93 inhibits the H + , K + -ATPase activity but strongly dissipates the proton gradient formed in the gastric membrane vesicles and reduces the volume of luminal space. KN-93 (0.5 μM) prevents increased LV developed pressure during action potential prolongation and early afterdepolarizations. Ca 2+ -independent CaM kinase activity is increased during early afterdepolarizations and this increase is prevented by KN-93. KN-93 (10 μM )significantly inhibits the activation of CaMKII/NF-κB signaling induced by elevated glucose, and subsequently decreases the expression of VEGF, iNOS and ICAM-1 in Müller cells.
KN-93 (1 mg/kg/day, i.p.) inhibits retinal vascular leakage induced by diabetes, and suppresses phosphorylation of CaMKII and NF-κB in diabetic retina.